

Reference:	FOI.10668.23
Subject:	The usage of intra-vitreous injections or implants
Date of Request:	11 January 2023

Requested:

Could you please tell me how many of the following intra-vitreous injections/implants has your trust administered in the four-month period from September to December 2022:

- Aflibercept
- Bevacizumab
- Brolucizumab
- Dexamethasone
- Faricimab
- Ranibizumab - Lucentis
- Ranibizumab - Ongavia

Response:

Hywel Dda University Health Board (UHB) provides, within the table overleaf, the number of each of the named intra-vitreous injections or implants administered, between 1 September and 31 December 2022.

Treatment	Number
Aflibercept	3,030
Bevacizumab	0
Brolucizumab	*
Dexamethasone	33
Faricimab	*
Ranibizumab – Lucentis	2,386
Ranibizumab – Ongavia	160

Where the figures in the tables have been replaced with an asterisk (*), the UHB is unable to provide you with the exact numbers, due to the low number of cases (5 and under), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the FoIA.

This information is protected by the Data Protection Act 2018 and the UK General Data Protection Regulations (UK GDPR), as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles 6 and 9 of the UK GDPR. This exemption is absolute and therefore, there is no requirement to apply the public interest test.

In reaching this decision, the Data Protection Act 2018/UK GDPR define personal data as data which relates to a living individual who can be identified solely from that data, or from that data and other information, which is in the possession of the data controller.